Pharming Group N.V annual free cash flow per share
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Free Cash Flow Per Share Growth & History (PHAR)
Pharming Group N.V's free cash flow per share was $0.08 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.08 | $0.08 | — |
| 2024 | 2024-12-31 | -$0.00 | $0.02 | — |
| 2023 | 2023-12-31 | -$0.03 | -$0.06 | — |
| 2022 | 2022-12-31 | $0.03 | -$0.01 | −23.01% |
| 2021 | 2021-12-31 | $0.04 | -$0.08 | −65.99% |
| 2020 | 2020-12-31 | $0.12 | $0.01 | +8.72% |
| 2019 | 2019-12-31 | $0.11 | — | — |
Pharming Group N.V quarterly free cash flow per share
Q4.25
Q1.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $0.02 | — | — |
| Q4 2025 | 2025-12-31 | $0.16 | — | — |
Pharming Group N.V free cash flow per share trends
Over the last five fiscal years, Pharming Group N.V's free cash flow per share decreased from $0.12 to $0.08, a change of -$0.05. The latest reported quarter, Q1 2026, shows $0.02.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...